VCIM
THRX

Velan Capital Investment Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Velan Capital Investment Management’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100,000
Closed -$888K – 39
2023
Q1 		$888K Buy
+100,000
New +$981K 0.76% 20

Other funds holding THRX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return

Velan Capital Investment Management's THRX Position: Q2 2023 in Review

Velan Capital Investment Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q2 2023, closing a stake of 100,000 shares — an estimated $888K sold.

Velan Capital Investment Management first reported a position in THRX in Q1 2023 and held it in 1 quarter. The position peaked at $888K in Q1 2023. 69 funds tracked by Wall St. Rank hold THRX as of Q2 2023.

  • Velan Capital Investment Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Velan Capital Investment Management sold 100,000 Theseus Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $888K.
  • Velan Capital Investment Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Velan Capital Investment Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $888K in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Velan Capital Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.